Meeting
2021 ASCO Annual Meeting
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.
Authors
Neal Shiv Chawla
City of Hope Comprehensive Cancer Center, Duarte, CA
Neal Shiv Chawla , Ted Kim , Travis Sherman , Jonathan Dang , Victoria S. Chua , Ania Moradkhani , Ishrat Bhuiyan , Nathalie Krkyan , Mitchel Fernando , Emma Colletti , William Feske , Kitty Zheng , Warren Allen Chow , Mark Agulnik , Doris Quon , Sant P. Chawla , Erlinda Maria Gordon , Arun S. Singh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT03886311
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11567)
DOI
10.1200/JCO.2021.39.15_suppl.11567
Abstract #
11567
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
![SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].](https://d201v5jt9ylckg.cloudfront.net/258/14787/186779/186779_poster_pv.jpg)
SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].
First Author: Erlinda Maria Gordon
Poster
2024 ASCO Annual Meeting
Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2023 ASCO Annual Meeting
Interim results of a phase 2 study using talimogene laherparepvec, nivolumab, and trabectedin for advanced leiomyosarcoma.
First Author: Neal Shiv Chawla
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon